(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 16 May 2002 (16.05.2002)

PCT

(10) International Publication Number WO 02/038177 A3

- (51) International Patent Classification⁷: A61K 39/39, A61P 31/00, 31/18, 35/00, 37/00, 25/18 // A61K 39/21, 39/00
- (21) International Application Number: PCT/US01/46943
- (22) International Filing Date:

8 November 2001 (08.11.2001)

- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:

60/247,100 10 November 2000 (10.11.2000) US 60/330,345 18 October 2001 (18.10.2001) US

- (71) Applicant (for all designated States except US): AMERICAN CYANAMID COMPANY [US/US]; A Corporation of the State of Maine, Five Giralda Farms, Madison, NJ 07940 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): HAGEN, Michael [CA/US]; 12 Summit Oaks, Pittsford, NY 14534 (US).
- (74) Agents: GORDON, Alan, M. et al.; American Home Products Corporation, Patent Law Department, 5 Giralda Farms, Madison, NJ 07940 (US).

- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- (88) Date of publication of the international search report: 16 January 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



/038177 A

(54) Title: ADJUVANT COMBINATION FORMULATIONS

(57) Abstract: The use of an aminoalkyl glucosamine phosphate compound, or a derivative or analog thereof, in combination with a cytokine or lymphokine such as granulocyte macrophage colony stimulating factor or interleukin-12, is useful as an adjuvant combination in an antigenic composition to enhance the immune response in a vertebrate host to a selected antigen.

In: onal Application No PCT/US 01/46943

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K39/39 A61P31/00

A61K39/39 A61P25/18 A6TP31/00 A61P31/18 //A61K39/21,A61K39/00 A61P35/00

A61P37/00

Relevant to claim No.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Category °

Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

Citation of document, with indication, where appropriate, of the relevant passages

EPO-Internal, BIOSIS, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Υ	WO 98 50399 A (RIBI IMMUNOCHEM INC) 12 November 1998 (1998-11-		1-13, 20-32, 39-42, 49-51, 56,61-66
	abstract page 2, line 18 - line 27 page 4, line 27 -page 5, line 2 page 6, line 7 - line 8 example 20 page 76, line 22 -page 88, line page 106, line 5 -page 113		
		-/	
X Furth	ner documents are listed in the continuation of box C.	χ Patent family members are listed	in annex.
"A" docume consid "E" earlier of filling d "L" docume which citation "O" docume other r	ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another n or other special reason (as specified) ent referring to an oral disclosure, use, exhibition or	"T" later document published after the inte or priority date and not in conflict with cited to understand the principle or th invention "X" document of particular relevance; the cannot be considered novel or cannot involve an inventive step when the do "Y" document of particular relevance; the cannot be considered to involve an in document is combined with one or ments, such combination being obvio in the art. "&" document member of the same patent	the application but early underlying the claimed invention be considered to cument is taken alone claimed invention ventive step when the one other such docuus to a person skilled
Date of the	actual completion of the international search	Date of mailing of the international sea	arch report
2	5 September 2002	10/10/2002	
Name and n	nailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer	
Form PCT/ISA/2	+ax: (+31-70) 340-3016 210 (second sheet) (July 1992)	100, 1	

In onal Application No
PUI/US 01/46943

C.(Continua	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	101703 01740943
Category °		Relevant to claim No.
Υ	WO 00 60084 A (SMITHKLINE BEECHAM BIOLOG; VINALS Y DE BASSOLS CARLOTA (BE); CORIX) 12 October 2000 (2000-10-12) page 22, line 6 -page 23, line 7 page 25, line 7 - line 19 page 26, line 19 - line 27	1-13, 20-32, 39-42, 49-51, 56,61-66
	claims 25,26 	
Y	US 5 980 911 A (CORNER LEIGH AUSTIN ET AL) 9 November 1999 (1999–11–09)	1-13, 20-32, 39-42, 49-51, 56,61-66
	the whole document 	
Υ	US 5 679 356 A (BONNEM ERIC M ET AL) 21 October 1997 (1997-10-21) cited in the application	1-13, 20-32, 39-42, 49-51, 56,61-66
	the whole document	,
Υ	WO 98 57659 A (SMITHKLINE BEECHAM BIOLOG; BOON THIERRY (BE); SILLA SILVIA (BE); U) 23 December 1998 (1998-12-23) the whole document	1-13, 20-32, 39-42, 49-51, 56,61-66
۸		14-16,
A	HAYNES B F ET AL: "HIV type 1 V3 region primer-induced antibody suppression is overcome by administration of C4-V3 peptides as a polyvalent immunogen." AIDS RESEARCH AND HUMAN RETROVIRUSES. UNITED STATES FEB 1995, vol. 11, no. 2, February 1995 (1995-02), pages 211-221, XP001108967 ISSN: 0889-2229 cited in the application abstract table 1	33-35, 43-45
	_/	

Int Ional Application No
PCI/US 01/46943

		<u> </u>	
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication,where appropriate, of the relevant passages	ļ	Relevant to claim No.
A	KURODA MARCELO J ET AL: "Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex." JOURNAL OF EXPERIMENTAL MEDICINE, vol. 187, no. 9, 4 May 1998 (1998-05-04), pages 1373-1381, XP002214739 ISSN: 0022-1007 cited in the application abstract column 2, paragraph 3		14,17, 33,36, 43,46
Α	LIAO HUA-XIN ET AL: "Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: Neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains." JOURNAL OF VIROLOGY, vol. 74, no. 1, January 2000 (2000-01), pages 254-263, XP002214740 ISSN: 0022-538X cited in the application abstract page 255, column 2, paragraph 1		14,18, 19,33, 37,38, 43,47,48
A	WO 99 27944 A (SCHENK DALE B ;ATHENA NEUROSCIENCES INC (US)) 10 June 1999 (1999-06-10) cited in the application abstract page 3, line 18 - line 28 page 14, line 30 - line 34	·	52-55, 57-60
		- 1	

rnational application No. PCT/US 01/46943

	Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
	This Inte	rnational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
	1. χ	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
		Although claims $29-50,56-60$ are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
	2.	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
	з. 🗌	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
	Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
	This Inte	ernational Searching Authority found multiple inventions in this international application, as follows:
	1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
	2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
	3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
	4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
	Remark	on Protest The additional search fees were accompanied by the applicant's protest.
		No protest accompanied the payment of additional search fees.
ĺ		

In onal Application No
PCT/US 01/46943

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9850399	A	12-11-1998	US AU BR CN EP HU JP NZ PL US WO US US	6113918 A 740663 B2 7474798 A 9809791 A 1265112 T 0983286 A1 0004147 A2 2002512623 T 500938 A 343205 A1 6355257 B1 9850399 A1 6303347 B1 2002048588 A1	05-09-2000 08-11-2001 27-11-1998 27-06-2000 30-08-2000 08-03-2000 28-04-2001 23-04-2002 31-05-2002 30-07-2001 12-03-2002 12-11-1998 16-10-2001 25-04-2002
WO 0060084	Α	12-10-2000	AU EP WO	4452900 A 1169450 A1 0060084 A1	23-10-2000 09-01-2002 12-10-2000
US 5980911	A	09-11-1999	AU AU WO CA EP NZ	694774 B2 2341195 A 9530436 A1 2189432 A1 0755266 A1 284778 A	30-07-1998 29-11-1995 16-11-1995 16-11-1995 29-01-1997 27-05-1998
US 5679356	A	21-10-1997	AU CN EP JP MX WO ZA	4662393 A 1091978 A 0651656 A1 7504683 T 9304089 A1 9401133 A1 9304890 A	31-01-1994 14-09-1994 10-05-1995 25-05-1995 31-01-1994 20-01-1994 14-04-1994
WO 9857659	A	23-12-1998	WO WO EP EP JP JP US	9857659 A1 9857660 A1 1001808 A1 0977589 A1 2002504135 T 2002504136 T 6375945 B1	23-12-1998 23-12-1998 24-05-2000 09-02-2000 05-02-2002 05-02-2002 23-04-2002
WO 9927944	A	10-06-1999	BG BR CN DE EP HR JP NO PL TR WO ZA	104562 A 9815357 A 2312920 A1 1281366 T 1033996 T1 200000379 A 1033996 A1 20000443 A1 0100627 A2 2002502802 T 20002784 A 342649 A1 200001608 T2 9927944 A1 1706199 A 9810932 A	31-01-2001 24-10-2000 10-06-1999 24-01-2001 07-06-2001 16-04-2001 13-09-2000 31-10-2000 28-06-2001 29-01-2002 31-07-2000 18-06-2001 23-07-2001 10-06-1999 16-06-1999 02-07-1999